Cerus
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development.
Industries
Nr. of Employees
large (251-1000)
Products
Pathogen-reduction system for platelets and plasma
A clinical-use system combining a photochemical agent and an illumination device with disposable processing sets to inactivate pathogens in platelet and plasma units.
Pathogen-reduced cryoprecipitated fibrinogen complex production
Regulatory-approved process and associated tools for producing pathogen-reduced cryoprecipitated fibrinogen complex for clinical treatment of fibrinogen deficiency and massive hemorrhage.
Pathogen-reduced red blood cell system (clinical-stage)
A red blood cell pathogen-reduction system under late-stage clinical development intended to inactivate pathogens in red blood cell units.
Pathogen-reduction system for platelets and plasma
A clinical-use system combining a photochemical agent and an illumination device with disposable processing sets to inactivate pathogens in platelet and plasma units.
Pathogen-reduced cryoprecipitated fibrinogen complex production
Regulatory-approved process and associated tools for producing pathogen-reduced cryoprecipitated fibrinogen complex for clinical treatment of fibrinogen deficiency and massive hemorrhage.
Pathogen-reduced red blood cell system (clinical-stage)
A red blood cell pathogen-reduction system under late-stage clinical development intended to inactivate pathogens in red blood cell units.
Services
Installation, training and technical support for pathogen-reduction systems
On-site and remote deployment, operator training, and ongoing technical support for blood center and hospital clients to operate pathogen-reduction devices and consumables.
Regulatory and clinical support for product adoption
Support for regulatory filings, clinical protocol design, data generation and presentation to facilitate regulatory approvals and clinical adoption of pathogen-reduction technologies.
Supply chain and inventory management services
Provisioning and distribution strategies including multi-location safety stock management for processing sets, illuminators, and spare parts to sustain clinical operations.
Educational programs and scientific webinars
Curated webinar series and podcast content on transfusion safety, bacterial contamination, pathogen inactivation, and pandemic preparedness for clinicians and blood center staff.
Installation, training and technical support for pathogen-reduction systems
On-site and remote deployment, operator training, and ongoing technical support for blood center and hospital clients to operate pathogen-reduction devices and consumables.
Regulatory and clinical support for product adoption
Support for regulatory filings, clinical protocol design, data generation and presentation to facilitate regulatory approvals and clinical adoption of pathogen-reduction technologies.
Supply chain and inventory management services
Provisioning and distribution strategies including multi-location safety stock management for processing sets, illuminators, and spare parts to sustain clinical operations.
Educational programs and scientific webinars
Curated webinar series and podcast content on transfusion safety, bacterial contamination, pathogen inactivation, and pandemic preparedness for clinicians and blood center staff.
Expertise Areas
- Pathogen reduction for blood components
- Clinical trial management for blood products
- Transfusion medicine and blood safety
- Device and disposables engineering for blood processing
Key Technologies
- Photochemical pathogen inactivation (psoralen + UVA)
- Illumination devices for pathogen inactivation
- Single-use processing sets for blood components
- Clinical trial platforms for late-stage device-biologic evaluation